"For most of her life, Joy Milne had a superpower that she was totally oblivious to," reports NPR. Long-time Slashdot reader doug141 explains what happened next: Milne's husband's natural odor changed when he was 31. He was diagnosed with Parkinson's at 45. When Joy walked into a Parkinson's support group, she smelled the same odor on everybody. A Parkinson's researcher tested her with blind samples from early stage patients, late-stage patients, and controls...
NPR tells the story of that test, which took place at the University of Edinburgh with a Parkinson's researcher named Tilo Kunath: [O]ut of all the samples, Joy made only one mistake. She identified a man in the control group, the group without Parkinson's, as having the disease. But many months later, Kunath says, that man actually approached him at an event and said, "Tilo, you're going to have to put me in the Parkinson's pile because I've just been diagnosed."

It was incontrovertible: Joy not only could smell Parkinson's but could smell it even in the absence of its typical medical presentation.

Kunath and fellow scientists published their work in ACS Central Science in March 2019, listing Joy as a co-author. Their research identified certain specific compounds that may contribute to the smell that Joy noticed on her husband and other Parkinson's patients. Joy and her super smelling abilities have opened up a whole new realm of research, Kunath says... Joy's superpower is so unusual that researchers all over the world have started working with her and have discovered that she can identify several kinds of illnesses — tuberculosis, Alzheimer's disease, cancer and diabetes.
Kunath says the ultimate goal is developing a new tool that can detect detect Parkinson's early. "Imagine a society where you could detect such a devastating condition before it's causing problems and then prevent the problems from even occurring."

While many coronavirus tests provide results within hours or days, America's Food and Drug Administration "has authorized the emergency use" of a new rapid coronavirus test from medical device manufacturer Abbott that could results in less than 15 minutes, reports NBC News: The FDA told Abbott it authorized the test's use after determining that "it is reasonable to believe that your product may be effective in diagnosing COVID-19," based on the scientific evidence presented. The agency added that the "known and potential benefits" of the test outweigh potential risks, such as false positives or negatives. The technology being used for the new test is similar to the one found in rapid flu tests, according to the FDA's authorization letter and Abbott.

The FDA also said Friday it has issued at least 19 other emergency use authorizations for diagnostic tests to detect COVID-19, and that it is working with more than 220 test developers who are expected to submit emergency-use authorization requests soon...

Abbott said it is ramping up production to deliver 50,000 tests to the U.S. health care system starting next week.

sciencehabit shared this article from Science magazine: For decades, astrophysicists have thought some sort of invisible dark matter must pervade the galaxies and hold them together, although its nature remains a mystery. Now, three physicists claim their observations of empty patches of sky rule out one possible explanation of the strange substance — that it is made out of unusual particles called sterile neutrinos. But others argue the data show no such thing.

"I think that for most of the people in the community this is the end of the story," says study author Benjamin Safdi, an astroparticle physicist at the University of Michigan, Ann Arbor. But Kevork Abazajian, a theoretical physicist at the University of California, Irvine, says the new analysis is badly flawed. "To be honest, this is one of the worst cases of cherry picking the data that I've seen," he says. In unpublished work, another group looked at similar patches of sky and saw the very same sign of sterile neutrinos that eluded Safdi...

Alexey Boyarsky, an astroparticle theorist at Leiden University, is unconvinced. "I think this paper is wrong," he says. Boyarsky says he and his colleagues performed a similar, unpublished analysis in 2018, also using images from XMM-Newton, and did see a 3.5-keV glow from the empty sky, just expected from peering through a halo of sterile neutrinos.

An anonymous reader quotes Wired: Next week, blood banks across the Netherlands are set to begin a nationwide experiment. As donations arrive — about 7,000 of them per week is the norm — they'll be screened with the usual battery of tests that keep the blood supply safe, plus one more: a test for antibodies to SARS-CoV-2, the virus that causes Covid-19. Then, in a few weeks, another batch of samples will get the same test. And after that, depending on the numbers, there could be further rounds. The blood donors should be fairly representative of Dutch adults ages 18 to 75, and most importantly, they'll all be healthy enough for blood donation — or at least outwardly so...

Identifying what proportion of the population has already been infected is key to making the right decisions about containment... [B]ecause no Covid-19-specific serological [antibody] tests have been fully vetted yet, the FDA's latest guidance is that they shouldn't be relied upon for diagnoses. But in epidemiology circles, those tests are a sought-after tool for understanding the scope of the disease. Since February — which was either three weeks or a lifetime ago — epidemiologists have been trying to get the full scope of the number of infections here in the U.S... [A]s the disease has continued to spread and a patchwork of local "stay at home" rules begins to bend the course of the disease, projecting who has the disease and where the hot spots are has become more difficult for models to capture.

Instead, you need boots-on-the-ground surveillance. In other words, to fill the gap created by a lack of diagnostic tests, you need more testing — but of a different sort. This time you have to know how many total people have already fought the bug, and how recently they've fought it. "Of all the data out there, if there was a good serological assay that was very specific about individuating recent cases, that would be the best data we could have," says Alex Perkins, an epidemiologist at the University of Notre Dame. The key, he says, is drawing blood from a representative sample that would show the true scope of unobserved infections... Another motivation to develop better blood tests is the potential to develop therapeutics from antibody-rich blood serum.
Wired is currently providing free access to stories about the coronavirus.

NASA has awarded SpaceX with a contract to supply Gateway, the moon-orbiting space station that the agency aims to start building in 2022, agency officials announced Friday. Space.com reports: Gateway is a key part of NASA's Artemis exploration program, which seeks to establish a sustainable, long-term human presence on and around the moon by the late 2020s. The small space station will serve as a jumping-off point for sorties, both crewed and uncrewed, to the lunar surface. SpaceX will help to keep the Gateway supplied, delivering scientific experiments and a variety of other gear to the outpost, NASA officials said. The company is guaranteed two missions under its newly announced Gateway Logistics Services contract.

SpaceX's robotic ISS resupply runs employ the company's Falcon 9 rocket and Dragon capsule, which can loft 13,200 lbs. (6,000 kilograms, or 6 metric tons) to low-Earth orbit. But SpaceX's Gateway missions will use different hardware: the huge Falcon Heavy rocket and a special capsule variant called Dragon XL. (SpaceX has also developed another Dragon version, Crew Dragon, which will fly astronauts to and from the ISS under yet another NASA contract.) Dragon XL will be able to carry more than 5 metric tons of cargo to the Gateway, SpaceX representatives said via Twitter Friday. Dragon cargo missions to the ISS typically last about a month from launch to splashdown. But Dragon XL will likely stay attached to the Gateway for six to 12 months at a time, NASA officials said. Other companies may end up joining SpaceX in the Gateway resupply game.

An anonymous reader quotes a report from Phys.Org: German researchers report in the journal Frontiers in Microbiology that they have identified and characterized a strain of bacteria capable of degrading some of the chemical building blocks of polyurethane. The team out of Germany managed to isolate a bacterium, Pseudomonas sp. TDA1, from a site rich in brittle plastic waste that shows promise in attacking some of the chemical bonds that make up polyurethane plastics. The researchers performed a genomic analysis to identify the degradation pathways at work. They made preliminary discoveries about the factors that help the microbe metabolize certain chemical compounds in plastic for energy. They also conducted other analyses and experiments to understand the bacterium's capabilities.

This particular strain is part of a group of bacteria that are well-known for their tolerance of toxic organic compounds and other forms of stress, according to Dr. Christian Eberlein with the Helmholtz Centre for Environmental Research-UFZ. He is a co-author on the paper who coordinated and supervised the work. "That trait is also named solvent-tolerance and is one form of extremophilic microorganisms," he said. In addition to polyurethane, the P4SB consortium, which includes the Helmholtz Centre for Environmental Research-UFZ, is also testing the efficacy of microbes to degrade plastics made of polyethylene terephthalate (PET), which is widely used in plastic water bottles.

NPR is reporting that some Wuhan residents in China who had tested positive earlier and then recovered from the disease are testing positive for the virus a second time. It's raising concerns of a possible second wave of cases, as China prepares to lift quarantine measures to allow residents to leave the epicenter of its outbreak next month. From the report: Based on data from several quarantine facilities in the city, which house patients for further observation after their discharge from hospitals, about 5%-10% of patients pronounced "recovered" have tested positive again. Some of those who retested positive appear to be asymptomatic carriers -- those who carry the virus and are possibly infectious but do not exhibit any of the illness's associated symptoms -- suggesting that the outbreak in Wuhan is not close to being over.

NPR has spoken by phone or exchanged text messages with four individuals in Wuhan who are part of this group of individuals testing positive a second time in March. All four said they had been sickened with the virus and tested positive, then were released from medical care in recent weeks after their condition improved and they tested negative. One of the Wuhan residents who spoke to NPR exhibited severe symptoms during their first round of illness and was eventually hospitalized. The second resident displayed only mild symptoms at first and was quarantined in one of more than a dozen makeshift treatment centers erected in Wuhan during the peak of the outbreak. But when both were tested a second time for the coronavirus on Sunday, March 22, as a precondition for seeking medical care for unrelated health issues, they tested positive for the coronavirus even though they exhibited none of the typical symptoms, such as a fever or dry cough. The time from their recovery and release to the retest ranged from a few days to a few weeks. One theory is that they were first given a false negative test result. Another theory is that, because the test amplifies tiny bits of DNA, residual virus from the initial infection could have falsely resulted in that second positive reading.

Apple launched its own coronavirus screening site and iOS app developed alongside the White House, CDC and FEMA. From a report: The site is pretty simple with basic information about best practices and safety tips alongside a basic screening tool which should give you a fairly solid idea on whether or not you need to be tested for COVID-19. The site which is -- of course -- accessible on mobile and desktop also includes some quick tips on social distancing, isolation, hand-washing, surface disinfecting and symptom monitoring. The app, which contains identical information to the site, is US-only at the moment while the website is available worldwide. Depending on your symptoms, the site will push you to get in contact with your health provider, contact emergency services or it will inform you that you likely do not need to be tested. It will not route you to a testing center directly. Apple says that its app and website gather or collect zero personal information about anyone using it.

President Trump on Friday signed into law the largest economic stimulus package in modern American history, backing a $2 trillion measure that expands on a Republican proposal issue last week called the CARES Act -- the Coronavirus Aid, Relief, and Economic Security Act. The New York Times reports: Under the law, the government will deliver direct payments and jobless benefits for individuals, money for states and a huge bailout fund for businesses battered by the crisis. Mr. Trump signed the measure in the Oval Office hours after the House approved it by voice vote and less than two days after the Senate unanimously passed it.

The legislation will send direct payments of $1,200 to millions of Americans, including those earning up to $75,000, and an additional $500 per child. It will substantially expand jobless aid, providing an additional 13 weeks and a four-month enhancement of benefits, and for the first time will extend the payments to freelancers and gig workers. The measure will also offer $377 billion in federally guaranteed loans to small businesses and establish a $500 billion government lending program for distressed companies reeling from the crisis, including allowing the administration the ability to take equity stakes in airlines that received aid to help compensate taxpayers. It will also send $100 billion to hospitals on the front lines of the pandemic. You can read the bill yourself here.

Ed Yong, writing for The Atlantic: The world is experienced at making flu vaccines and does so every year. But there are no existing vaccines for coronaviruses -- until now, these viruses seemed to cause diseases that were mild or rare -- so researchers must start from scratch. The first steps have been impressively quick. Last Monday, a possible vaccine created by Moderna and the National Institutes of Health went into early clinical testing. That marks a 63-day gap between scientists sequencing the virus's genes for the first time and doctors injecting a vaccine candidate into a person's arm. "It's overwhelmingly the world record," Fauci said. But it's also the fastest step among many subsequent slow ones. The initial trial will simply tell researchers if the vaccine seems safe, and if it can actually mobilize the immune system. Researchers will then need to check that it actually prevents infection from SARS-CoV-2. They'll need to do animal tests and large-scale trials to ensure that the vaccine doesn't cause severe side effects. They'll need to work out what dose is required, how many shots people need, if the vaccine works in elderly people, and if it requires other chemicals to boost its effectiveness.

"Even if it works, they don't have an easy way to manufacture it at a massive scale," said Seth Berkley of Gavi. That's because Moderna is using a new approach to vaccination. Existing vaccines work by providing the body with inactivated or fragmented viruses, allowing the immune system to prep its defenses ahead of time. By contrast, Moderna's vaccine comprises a sliver of SARS-CoV-2's genetic material -- its RNA. The idea is that the body can use this sliver to build its own viral fragments, which would then form the basis of the immune system's preparations. This approach works in animals, but is unproven in humans. By contrast, French scientists are trying to modify the existing measles vaccine using fragments of the new coronavirus. "The advantage of that is that if we needed hundreds of doses tomorrow, a lot of plants in the world know how to do it," Berkley said. No matter which strategy is faster, Berkley and others estimate that it will take 12 to 18 months to develop a proven vaccine, and then longer still to make it, ship it, and inject it into people's arms.

For weeks, Prime Minister Boris Johnson was a defiant holdout among Western leaders in refusing to lock down his country against the spread of the coronavirus. On Friday, he became the first of those leaders known to have contracted the disease. From a report: Mr. Johnson's diagnosis, confirmed in a test on Thursday, threatened to throw an already rattled British government into turmoil. Fears of a wider contagion grew, as another senior official disclosed he was also infected. Britain faced the alarming prospect of having to confront its greatest crisis since World War II with much of its leadership in quarantine. Mr. Johnson, 55, insisted he would not relinquish his duties. In a remarkable two-minute video posted on Twitter, he used his own case as a sort of teachable moment for the country, appealing to people to work from home and comply with the more drastic social distancing measures he put in place last Monday.

The New York Times has made one of the most comprehensive datasets of coronavirus cases in the United States publicly available in response to requests from researchers, scientists, government officials and businesses who would like access to the data to better understand the virus and model what may come next. From a report: The Times initially began tracking cases in late January after it became clear that no federal government agency was providing the public with an accurate, up-to-date record of cases, tracked to the county level, of people in the U.S. who had tested positive for the virus. The Times led effort has grown from a handful of correspondents to a team of several dozen journalists, including data scientists and student journalists from Northwestern University, the University of Missouri and the University of Nebraska-Lincoln, working around the clock to record details about every case. The Times is committed to collecting as much data as possible in connection with the outbreak and is collaborating with the University of California, Berkeley, on an effort in California. By Friday, March 27, The Times had tracked more than 85,000 cases in all 50 states, the District of Columbia and three U.S. territories, over the past eight weeks. More than 1,200 people in the U.S. have died so far.

schwit1 shares a report from UPI: The first official mission for the new U.S. Space Force lifted off from Florida at 4:18 p.m. EDT on Thursday into a virtually cloudless sky with a military communications satellite aboard. A United Launch Alliance Atlas V rocket emblazoned with the Space Force chevron logo carried the satellite toward orbit from Cape Canaveral Air Force Stations Complex 41.

The payload on board is the sixth in a constellation of next-generation satellites known as Advanced Extremely High Frequency or AEHF. The satellite system, developed by Lockheed Martin, has upgraded anti-jamming capability. Northrop Grumman is the manufacturer. The new network provides global coverage for national leaders and tactical warfighters operating on the ground, at sea or in the air, Lockheed said. The anti-jam system also serves international allies such as Canada, the Netherlands, United Kingdom and Australia.

Engineers from Stanford University developed a motorized exoskeleton rig that attaches around the ankle and foot and found that it made running 15 percent easier. "They explained that when the exoskeleton's motor is switched on, it reduces the energy cost of running and allows the user to run longer than they're usually capable of," reports Engadget. "The device can also boost a runner's speed by as much as 10 percent." From the report: Here's how the exoskeleton works: Its motors tug a cable running through the back of the rig from the heel to the calf. That pulls the foot upward during the toe-off, extending the ankle at the end of every step. Team member and Stanford grad student Delaney Miller said: "Powered assistance took off a lot of the energy burden of the calf muscles. It was very springy and very bouncy compared to normal running. Speaking from experience, that feels really good. When the device is providing that assistance, you feel like you could run forever."

140Mandak262Jamuna writes: Elon Musk announced that the Gigafactory in Buffalo, New York, making solar roof tiles and battery packs for home energy storage is switching to making ventilators in collaboration with Medtronic. "Days after offering 1,255 free ventilators to help deal with the coronavirus outbreak, Tesla boss Elon Musk said the company's New York factory will restart to make more," reports CNET.

"Giga New York will reopen for ventilator production as soon as humanly possible. We will do anything in our power to help the citizens of New York," he tweeted on Wednesday. New York Gov. Andrew Cuomo said the state needs 30,000 ventilators at the peak and they have 400 at hand.

An anonymous reader quotes a report from The New York Times: Scientists warned that the United States someday would become the country hardest hit by the coronavirus pandemic. That moment arrived on Thursday. In the United States, at least 81,321 people are known to have been infected with the coronavirus, including more than 1,000 deaths -- more cases than China, Italy or any other country has seen, according to data gathered by The New York Times.

With 330 million residents, the United States is the world's third most populous nation, meaning it provides a vast pool of people who can potentially get Covid-19, the disease caused by the virus. And it is a sprawling, cacophonous democracy, where states set their own policies and President Trump has sent mixed messages about the scale of the danger and how to fight it, ensuring there was no coherent, unified response to a grave public health threat. A series of missteps and lost opportunities dogged the nation's response. Among them: a failure to take the pandemic seriously even as it engulfed China, a deeply flawed effort to provide broad testing for the virus that left the country blind to the extent of the crisis, and a dire shortage of masks and protective gear to protect doctors and nurses on the front lines, as well as ventilators to keep the critically ill alive. "The world will be a different place when the pandemic is over," the report concludes. It suggests India may become the next global hotspot for virus cases as "it, too, is a vast democracy with deep internal divisions. But its population, 1.3 billion, is far larger, and its people are crowded even more tightly into megacities."

A new consortium of top scientists will be able to use some of the world's most advanced supercomputers to look for solutions. From a report: Advanced computers have defeated chess masters and learned how to pick through mountains of data to recognize faces and voices. Now, a billionaire developer of software and artificial intelligence is teaming up with top universities and companies to see if A.I. can help curb the current and future pandemics. Thomas M. Siebel, founder and chief executive of C3.ai, an artificial intelligence company in Redwood City, Calif., said the public-private consortium would spend $367 million in its initial five years, aiming its first awards at finding ways to slow the new coronavirus that is sweeping the globe. "I cannot imagine a more important use of A.I.," Mr. Siebel said in an interview.

Known as the C3.ai Digital Transformation Institute, the new research consortium includes commitments from Princeton, Carnegie Mellon, the Massachusetts Institute of Technology, the University of California, the University of Illinois and the University of Chicago, as well as C3.ai and Microsoft. It seeks to put top scientists onto gargantuan social problems with the help of A.I. -- its first challenge being the pandemic. The new institute will seek new ways of slowing the pathogen's spread, speeding the development of medical treatments, designing and repurposing drugs, planning clinical trials, predicting the disease's evolution, judging the value of interventions, improving public health strategies and finding better ways in the future to fight infectious outbreaks.

According to Johns Hopkins University, there are now more than 510,000 confirmed COVID-19 cases worldwide and more than 22,000 people have died from the new coronavirus. While China still has the most confirmed cases, the United States and Italy are close behind. CBS News reports: In the United States, more than 1,000 people have died and more than 75,000 people have been infected. An unprecedented number of Americans applied for unemployment benefits last week as the virus shuttered businesses and normal life across large swaths of the country came to a halt. Roughly 3.3 million people filed a claim for jobless aid in the week ending March 21 -- a nearly fivefold increase over the previous weekly record set in 1982. The Senate has passed an unprecedented $2 trillion relief package to help workers, businesses and the severely strained health care system survive the pandemic. UPDATE: The United States now leads the world with confirmed coronavirus cases. "[A]t least 81,321 people are known to have been infected with the coronavirus, including more than 1,000 deaths -- more cases than China, Italy or any other country has seen," reports The New York Times.

Isaac Chotiner of The New Yorker interviews Naomi Oreskes, a professor of the history of science at Harvard who has focussed much of her career on examining distrust of science in the U.S.: Chotiner: This idea that we reject science because it clashes with our beliefs or experience -- how does that explain why people in Miami, whose homes are going to be flooded, reject global-warming science? Is it partisanship?

Oreskes: The phrase I used was implicatory denial. What we found in "Merchants of Doubt" was that the original merchants of doubt, the people who started the whole thing, way back in the late nineteen-eighties, didn't want to accept the implication that capitalism, as we know it, had failed -- that climate change was a huge market failure and that there was a need for some kind of significant government intervention in the marketplace to address it. So, rather than accept that implication, they questioned the science. Now these things get complicated. People are complicated. One of the things that's happened with climate change over the last thirty years is that, because climate-change denial got picked up by the Republican Party as a political platform, it became polarized according to partisan politics, which is different than, say, vaccination rejection.

And so then it became a talking point for Republicans, and then it became tribal. So now you have this deeply polarized situation in the United States where your views on climate change align very, very strongly with your party affiliation. And now we see a cognitive dissonance. Let's say you live in Florida, and you're now seeing flooding on a rather regular basis. This is completely consistent with the scientific evidence, but you don't accept it as proof of the science. You say, "Oh, well, we've always had flooding, or maybe it's a natural variable." You come up with excuses not to accept the thing that you don't want to accept.

As the coronavirus pandemic continues to affect people all over the globe, Airbnb is stepping up with a plan to offer free or subsidized housing to people working on the disease's front lines, namely health care professionals, emergency workers and relief personnel. From a report: The company announced today that it will provide "free or subsidized housing" for 100,000 people working as frontline healthcare, relief for first response professionals focused on stemming the COVID-19 crisis. Airbnb's effort will work by allowing Hosts on its platform to opt-in to making their space available, with any fees that Airbnb would normally charge for using its platform waived for those who participate.